Meeting
2017 ASCO Annual Meeting
An open-label, phase II study of tipifarnib for the treatment of HRAS mutant solid tumors, including squamous cell carcinomas of the head and neck.
Authors
Alan Loh Ho
Memorial Sloan Kettering Cancer Center, New York, NY
Alan Loh Ho , Nicole Grace Chau , Deborah Jean Lee Wong , Maria E. Cabanillas , Jessica Ruth Bauman , Keith Christopher Bible , Marcia S. Brose , Emiliano Calvo , Valentina Boni , Francis Burrows , Carrie L. Melvin , Catherine Rose Scholz , Antonio Gualberto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT02383927
Citation
J Clin Oncol 35, 2017 (suppl; abstr TPS2618)
DOI
10.1200/JCO.2017.35.15_suppl.TPS2618
Abstract #
TPS2618
Poster Bd #
99a
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
SGNTV-001: Open label phase 2 study of tisotumab vedotin for locally advanced or metastatic disease in solid tumors.
First Author: David S. Hong
Poster
2023 ASCO Annual Meeting
SI-B001 plus chemotherapy in patients with locally advanced or metastatic EGFR/ALK wild-type non-small cell lung cancer: A phase II, multicenter, open-label study.
First Author: Yuanyuan Zhao
Poster
2023 ASCO Annual Meeting
DURTRERAD: A phase II open-label study evaluating feasibility and efficacy of durvalumab (D) and durvalumab plus tremelimumab (DT) in combination with radiotherapy (RT) in non-resectable locally advanced HPV-negative head and neck squamous cell carcinoma (LA-HNSCC).
First Author: Ulrich Keilholz
Poster
2023 ASCO Annual Meeting
A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.
First Author: Jordi Rodon Ahnert